NCT04205305View on ClinicalTrials.gov

Outcome in Patients Treated with Intraarterial Thrombectomy - OptiMAL Blood Pressure Control (OPTIMAL-BP)

PHASE4CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

July 23, 2023

Study Completion Date

July 23, 2023

Conditions
Ischemic Stroke
Interventions
DRUG

conventional blood pressure control (labetalol, nicardipine)

After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<180 mmHg.

DRUG

intensive blood pressure control (labetalol, nicardipine)

After successful recanalization, appropriate antihypertension medication is administered to control systolic blood pressure \<140 mmHg.

Trial Locations (1)

120-752

Department of Neurology, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT04205305 - Outcome in Patients Treated with Intraarterial Thrombectomy - OptiMAL Blood Pressure Control (OPTIMAL-BP) | Biotech Hunter | Biotech Hunter